Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Acute Flaccid Myelitis in the United States: 2015-2017.

Ayers T, Lopez A, Lee A, Kambhampati A, Nix WA, Henderson E, Rogers S, Weldon WC, Oberste MS, Sejvar J, Hopkins SE, Pallansch MA, Routh JA, Patel M.

Pediatrics. 2019 Oct 7. pii: e20191619. doi: 10.1542/peds.2019-1619. [Epub ahead of print]

PMID:
31591135
2.

Poliopolis: pushing boundaries of scientific innovations for disease eradication.

Van Damme P, Coster I, Bandyopadhyay AS, Suykens L, Rudelsheim P, Neels P, Oberste MS, Weldon WC, Clemens R, Revets H.

Future Microbiol. 2019 Sep 4. doi: 10.2217/fmb-2019-0196. [Epub ahead of print]

3.

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.

Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, Kew OM, Konopka-Anstadt JL, Burns CC, Konz J, Wahid R, Gast C.

Lancet. 2019 Jul 13;394(10193):148-158. doi: 10.1016/S0140-6736(19)31279-6. Epub 2019 Jun 4.

4.

Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A.

Lancet. 2019 Jun 29;393(10191):2624-2634. doi: 10.1016/S0140-6736(19)30503-3. Epub 2019 May 16.

PMID:
31104832
5.

Extended delivery of vaccines to the skin improves immune responses.

Joyce JC, Sella HE, Jost H, Mistilis MJ, Esser ES, Pradhan P, Toy R, Collins ML, Rota PA, Roy K, Skountzou I, Compans RW, Oberste MS, Weldon WC, Norman JJ, Prausnitz MR.

J Control Release. 2019 Jun 28;304:135-145. doi: 10.1016/j.jconrel.2019.05.006. Epub 2019 May 6. French.

PMID:
31071375
6.

Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam.

Huyen DTT, Mach O, Thanh Trung N, Thai PQ, Thang HV, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW, Anh DD.

J Infect Dis. 2019 Jul 2;220(3):386-391. doi: 10.1093/infdis/jiz124.

PMID:
30869149
7.

Neutralizing Antibody against Enterovirus D68 in Children and Adults before 2014 Outbreak, Kansas City, Missouri, USA1.

Harrison CJ, Weldon WC, Pahud BA, Jackson MA, Oberste MS, Selvarangan R.

Emerg Infect Dis. 2019 Mar;25(3):585-588. doi: 10.3201/eid2503.180960.

8.

Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.

Gamage D, Mach O, Ginige S, Weldon WC, Oberste MS, Jeyaseelan V, Sutter RW.

J Infect Dis. 2019 May 24;219(12):1887-1892. doi: 10.1093/infdis/jiz026.

PMID:
30649505
9.

Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.

Gaensbauer JT, Gast C, Bandyopadhyay AS, O'Ryan M, Saez-Llorens X, Rivera L, Lopez-Medina E, Melgar M, Weldon WC, Oberste MS, Rüttimann R, Clemens R, Asturias EJ.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S57-S65. doi: 10.1093/cid/ciy649.

10.

Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, Pallansch MA, Oberste MS, Villinger F, Orenstein W, Murali-Krishna K.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S66-S77. doi: 10.1093/cid/ciy634.

11.

Trends in Poliovirus Seroprevalence in Kano State, Northern Nigeria.

Verma H, Iliyasu Z, Craig KT, Molodecky NA, Urua U, Jibir BW, Gwarzo GD, Gajida AU, McDonald S, Weldon WC, Oberste MS, Braka F, Mkanda P, Sutter RW.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S103-S109. doi: 10.1093/cid/ciy637.

PMID:
30376090
12.

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.

Brickley EB, Wieland-Alter W, Connor RI, Ackerman ME, Boesch AW, Arita M, Weldon WC, O'Ryan MG, Bandyopadhyay AS, Wright PF.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S42-S50. doi: 10.1093/cid/ciy603.

13.

Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.

Gamage D, Mach O, Palihawadana P, Zhang Y, Weldon WC, Oberste MS, Gunasena S, Sutter RW.

J Infect Dis. 2018 Nov 5;218(12):1876-1882. doi: 10.1093/infdis/jiy389.

PMID:
29982532
14.

Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.

Zaman K, Estívariz CF, Morales M, Yunus M, Snider CJ, Gary HE Jr, Weldon WC, Oberste MS, Wassilak SG, Pallansch MA, Anand A.

Lancet Infect Dis. 2018 Jun;18(6):657-665. doi: 10.1016/S1473-3099(18)30113-0. Epub 2018 Mar 20.

PMID:
29571817
15.

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar.

Razafindratsimandresy R, Mach O, Heraud JM, Bernardson B, Weldon WC, Oberste MS, Sutter RW.

Heliyon. 2018 Mar 7;4(3):e00563. doi: 10.1016/j.heliyon.2018.e00563. eCollection 2018 Mar.

16.

Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures.

White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE Jr, Maes EF, Oberste MS, Snider CJ, Anand A, Chen D.

Biologicals. 2018 May;53:30-38. doi: 10.1016/j.biologicals.2018.03.002. Epub 2018 Mar 14.

17.

Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017.

Hussain I, Mach O, Hamid NA, Bhatti ZS, Moore DD, Oberste MS, Khan S, Khan H, Weldon WC, Sutter RW, Bhutta ZA, Soofi SB.

Vaccine. 2018 Apr 5;36(15):1921-1924. doi: 10.1016/j.vaccine.2018.02.055. Epub 2018 Mar 3.

18.

Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.

Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Sutter RW, Zaidi AKM.

Vaccine. 2018 Mar 20;36(13):1766-1771. doi: 10.1016/j.vaccine.2018.02.051. Epub 2018 Feb 21.

19.

Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Shaw J, Jorba J, Zhao K, Iber J, Chen Q, Adu F, Adeniji A, Bukbuk D, Baba M, Henderson E, Dybdahl-Sissoko N, McDonald S, Weldon WC, Gumede N, Oberste MS, Kew OM, Burns CC.

J Virol. 2018 Apr 13;92(9). pii: e01949-17. doi: 10.1128/JVI.01949-17. Print 2018 May 1.

20.

Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa.

Guindo O, Mach O, Doumbia S, Ekra DK, Beavogui AH, Weldon WC, Oberste MS, Sutter RW.

Vaccine. 2018 Feb 14;36(8):1027-1031. doi: 10.1016/j.vaccine.2018.01.022. Epub 2018 Jan 19.

PMID:
29358054
21.

Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.

Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, Ackerman ME, Arita M, Oberste MS, Weldon WC, Sáez-Llorens X, Bandyopadhyay AS, Wright PF.

J Infect Dis. 2018 Jan 17;217(3):371-380. doi: 10.1093/infdis/jix556.

22.

Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae).

Rhoden E, Nix WA, Weldon WC, Selvarangan R.

Antiviral Res. 2018 Jan;149:75-77. doi: 10.1016/j.antiviral.2017.11.011. Epub 2017 Nov 15.

PMID:
29155163
23.

Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.

Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Steven Oberste M, Zaidi SS, Alam MM, Quadri F, Sutter RW, Zaidi AKM.

J Infect Dis. 2018 Jan 17;217(3):443-450. doi: 10.1093/infdis/jix577.

PMID:
29126173
24.

High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses.

Muller DA, Fernando GJP, Owens NS, Agyei-Yeboah C, Wei JCJ, Depelsenaire ACI, Forster A, Fahey P, Weldon WC, Oberste MS, Young PR, Kendall MAF.

Sci Rep. 2017 Oct 3;7(1):12644. doi: 10.1038/s41598-017-13011-0.

25.

Survey of poliovirus antibodies in Borno and Yobe States, North-Eastern Nigeria.

Gofama MM, Verma H, Abdullahi H, Molodecky NA, Craig KT, Urua UA, Garba MA, Alhaji MA, Weldon WC, Oberste MS, Braka F, Muhammad AJG, Sutter RW.

PLoS One. 2017 Sep 26;12(9):e0185284. doi: 10.1371/journal.pone.0185284. eCollection 2017.

26.

Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan: A Cross-Sectional Survey 2015-2016.

Hussain I, Mach O, Habib A, Bhatti Z, Suhag Z, Oberste MS, Weldon WC, Sutter RW, Soofi SB, Bhutta ZA.

Pediatr Infect Dis J. 2017 Sep;36(9):e230-e236. doi: 10.1097/INF.0000000000001622.

PMID:
28806355
27.

Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.

Saleem AF, Mach O, Yousafzai MT, Khan A, Weldon WC, Oberste MS, Sutter RW, Zaidi AKM.

Vaccine. 2017 May 31;35(24):3209-3214. doi: 10.1016/j.vaccine.2017.04.075. Epub 2017 May 4.

28.

Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.

Lopez-Medina E, Melgar M, Gaensbauer JT, Bandyopadhyay AS, Borate BR, Weldon WC, Rüttimann R, Ward J, Clemens R, Asturias EJ.

Vaccine. 2017 Jun 16;35(28):3591-3597. doi: 10.1016/j.vaccine.2017.04.041. Epub 2017 Apr 25.

29.

Arm Paralysis After Routine Childhood Vaccinations: Application of Advanced Molecular Methods to the Causality Assessment of an Adverse Event After Immunization.

Shaw J, Halsey NA, Weinberg A, Scott Schmid D, George KS, Weldon WC, Jordan M, Bryant PW, LaRussa PS, Bradshaw DY, Harrington T, Gershon A.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e161-e164. doi: 10.1093/jpids/piw084.

30.

Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013.

Wallace GS, Pahud BA, Weldon WC, Curns AT, Oberste MS, Harrison CJ.

Hum Vaccin Immunother. 2017 Apr 3;13(4):776-783. doi: 10.1080/21645515.2016.1255386. Epub 2017 Jan 6.

31.

Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria.

Iliyasu Z, Verma H, Craig KT, Nwaze E, Ahmad-Shehu A, Jibir BW, Gwarzo GD, Gajida AU, Weldon WC, Steven Oberste M, Takane M, Mkanda P, Muhammad AJG, Sutter RW.

Vaccine. 2016 Sep 30;34(42):5125-5131. doi: 10.1016/j.vaccine.2016.08.058. Epub 2016 Aug 31.

32.

Seroprevalence of Poliovirus Antibodies in the United States Population, 2009-2010.

Wallace GS, Curns AT, Weldon WC, Oberste MS.

BMC Public Health. 2016 Aug 5;16:721. doi: 10.1186/s12889-016-3386-1.

33.

Effect of booster doses of poliovirus vaccine in previously vaccinated children, Clinical Trial Results 2013.

Habib MA, Soofi S, Mach O, Samejo T, Alam D, Bhatti Z, Weldon WC, Oberste SM, Sutter R, Bhutta ZA.

Vaccine. 2016 Jul 19;34(33):3803-9. doi: 10.1016/j.vaccine.2016.05.065. Epub 2016 Jun 16.

PMID:
27269054
34.

Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.

Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, O'Ryan G M, Jimeno J, Clemens SA, Ward J, Rüttimann R; Latin American IPV001BMG Study Group.

Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Erratum in: Lancet. 2016 Jul 9;388(10040):e2.

PMID:
27212429
35.

Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes.

Chan HT, Xiao Y, Weldon WC, Oberste SM, Chumakov K, Daniell H.

Plant Biotechnol J. 2016 Nov;14(11):2190-2200. doi: 10.1111/pbi.12575. Epub 2016 Jun 1.

36.

The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal.

Cardemil CV, Estivariz C, Shrestha L, Sherchand JB, Sharma A, Gary HE Jr, Oberste MS, Weldon WC 3rd, Bowen MD, Vinjé J, Schluter WW, Anand A, Mach O, Chu SY.

Vaccine. 2016 May 11;34(22):2519-26. doi: 10.1016/j.vaccine.2016.03.027. Epub 2016 Apr 13.

PMID:
27085172
37.

Standardized Methods for Detection of Poliovirus Antibodies.

Weldon WC, Oberste MS, Pallansch MA.

Methods Mol Biol. 2016;1387:145-76. doi: 10.1007/978-1-4939-3292-4_8.

PMID:
26983734
38.

Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses.

Muller DA, Pearson FE, Fernando GJ, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, Young PR, Kendall MA.

Sci Rep. 2016 Feb 25;6:22094. doi: 10.1038/srep22094.

39.

Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Mar;16(3):321-30. doi: 10.1016/S1473-3099(15)00488-0. Epub 2015 Dec 21.

PMID:
26719058
40.

Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial.

Mychaleckyj JC, Haque R, Carmolli M, Zhang D, Colgate ER, Nayak U, Taniuchi M, Dickson D, Weldon WC, Oberste MS, Zaman K, Houpt ER, Alam M, Kirkpatrick BD, Petri WA Jr.

Vaccine. 2016 Jan 12;34(3):358-66. doi: 10.1016/j.vaccine.2015.11.046. Epub 2015 Nov 28.

41.

Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.

van der Sanden SM, Wu W, Dybdahl-Sissoko N, Weldon WC, Brooks P, O'Donnell J, Jones LP, Brown C, Tompkins SM, Oberste MS, Karpilow J, Tripp RA.

J Virol. 2015 Nov 18;90(4):1694-704. doi: 10.1128/JVI.01464-15. Print 2016 Feb 15.

42.

Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.

Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, Heffelfinger JD, Pallansch MA.

Vaccine. 2015 Nov 27;33(48):6816-22. doi: 10.1016/j.vaccine.2015.09.039. Epub 2015 Oct 23.

PMID:
26476367
43.

Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.

O'Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, Clemens R, Orenstein W, Jimeno J, Rüttimann R, Costa Clemens SA; Chilean IPV/bOPV study group.

Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Erratum in: Lancet Infect Dis. 2015 Oct;15(10):1130.

PMID:
26318714
44.

Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products.

Zhang Y, Moore DD, Nix WA, Oberste MS, Weldon WC.

J Clin Virol. 2015 Aug;69:172-5. doi: 10.1016/j.jcv.2015.06.086. Epub 2015 Jun 19.

45.

Achieving high seroprevalence against polioviruses in Sri Lanka--results from a serological survey, 2014.

Gamage D, Palihawadana P, Mach O, Weldon WC, Oberste SM, Sutter RW.

J Epidemiol Glob Health. 2015 Dec;5(4 Suppl 1):S67-71. doi: 10.1016/j.jegh.2015.06.004. Epub 2015 Jul 9.

46.

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.

Estívariz CF, Anand A, Gary HE Jr, Rahman M, Islam J, Bari TI, Wassilak SG, Chu SY, Weldon WC, Pallansch MA, Heffelfinger JD, Luby SP, Zaman K.

Lancet Infect Dis. 2015 Aug;15(8):898-904. doi: 10.1016/S1473-3099(15)00094-8. Epub 2015 Jun 17.

PMID:
26093980
47.

Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.

Mir F, Quadri F, Mach O, Ahmed I, Bhatti Z, Khan A, Rehman NU, Durry E, Salama M, Oberste SM, Weldon WC, Sutter RW, Zaidi AK.

Lancet Infect Dis. 2015 Aug;15(8):889-97. doi: 10.1016/S1473-3099(15)00093-6. Epub 2015 Jun 17.

48.

Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.

Saleem AF, Mach O, Quadri F, Khan A, Bhatti Z, Rehman NU, Zaidi S, Weldon WC, Oberste SM, Salama M, Sutter RW, Zaidi AK.

Vaccine. 2015 Jun 4;33(24):2757-63. doi: 10.1016/j.vaccine.2015.04.055. Epub 2015 Apr 24.

49.

The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.

Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD.

Vaccine. 2015 Apr 15;33(16):1909-15. doi: 10.1016/j.vaccine.2015.02.069. Epub 2015 Mar 9.

50.

Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.

Edens C, Dybdahl-Sissoko NC, Weldon WC, Oberste MS, Prausnitz MR.

Vaccine. 2015 Sep 8;33(37):4683-90. doi: 10.1016/j.vaccine.2015.01.089. Epub 2015 Mar 3.

PMID:
25749246

Supplemental Content

Loading ...
Support Center